Biotech stock indices continued their climb to new heights, posting >20% in 1H13. Industry raised $1.2 billion from 19 IPOs in 2Q13, including listings from Cambridge, Mass.–based innovators bluebird bio and Epizyme. The last time IPOs pulled in >$1 billion was 2Q07, when 22 new listings raised $1.4 billion. Together with a nearly fourfold uptick in follow-on deals, $10.2 billion was raised this quarter, excluding partnership monies. Venture money was also up to $1.9 billion.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. 2Q13—an IPO revival. Nat Biotechnol 31, 672 (2013). https://doi.org/10.1038/nbt.2663
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2663
